Roivant Sciences Ltd. Business Finance Contracts & Agreements
18 Contracts & Agreements
- Funding Agreements (2 contracts)
- Investor Rights Agreements (2)
- Purchase Agreements (4)
- Registration Rights Agreements (1)
- Release Agreements (1)
- Share Agreements (1)
- Shareholders Agreements (3)
- Stock Agreements (1)
- Subscription Agreements (1)
- Underwriting Agreements (2)
- Form of Common Share Purchase and Sale Agreement (Filed With SEC on September 29, 2023)
- Amended & Restated Roivant Sciences Ltd. Employee Stock Purchase Plan (Filed With SEC on June 28, 2023)
- Investor Rights Agreement dated as of November 21, 2022 (Filed With SEC on February 13, 2023)
- Underwriting Agreement, dated as of February 2, 2023, by and among Roivant Sciences Ltd., Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and Company, LLC and Cantor Fitzgerald... (Filed With SEC on February 7, 2023)
- Underwriting Agreement, dated as of November 8, 2022, by and among Roivant Sciences Ltd., Cantor Fitzgerald & Co., and the Selling Shareholders named therein (Filed With SEC on November 10, 2022)
- Investor Rights Agreement, dated as of September 13, 2021, by and among Priovant Holdings, Inc., Roivant Sciences Ltd. and Pfizer Inc (Filed With SEC on June 28, 2022)
- Amendment No. 1 to the Support Agreement, dated as of June 9, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp., Patient Square Capital LLC and certain... (Filed With SEC on June 28, 2022)
- Form of Transaction Support Agreement, dated as of May 1, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp. and certain shareholders of Roivant... (Filed With SEC on June 28, 2022)
- Sponsor Support Agreement, dated as of May 1, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp., Patient Square Capital LLC and certain shareholders of... (Filed With SEC on June 28, 2022)
- Form of Subscription Agreement (Filed With SEC on June 28, 2022)
- Third Amended and Restated Registration Rights Agreement, dated as of May 1, 2021, by and among Roivant Sciences Ltd. and the parties thereto (Filed With SEC on June 28, 2022)
- Common Shares Purchase Agreement, dated February 14, 2022, between Roivant Sciences Ltd. and CF Principal Investments LLC (Filed With SEC on February 14, 2022)
- Agreement and General Release Between Roivant Sciences Ltd., Roivant Sciences, Inc. and Benjamin Zimmer (Filed With SEC on November 15, 2021)
- First Amendment to Funding Agreement dated as of October 11, 2018, by and between Dermavant Sciences GmBH and NovaQuest Co-Investment Fund VIII, L.P (Filed With SEC on May 14, 2021)
- Funding Agreement, dated as of July 10, 2018, by and between Demavant Sciences GmBH and NovaQuest Co-Investment Fund VIII, L.P (Filed With SEC on May 14, 2021)
- First Amendment to the Asset Purchase Agreement, dated as of August 31, 2012, by and between Glaxo Group Limited and Welichem Biotech, Inc (Filed With SEC on May 14, 2021)
- Asset Purchase Agreement, dated as of May 29, 2012, by and between Glaxo Group Limited and Welichem Biotech Inc (Filed With SEC on May 14, 2021)
- Asset Purchase Agreement, dated as of July 10, 2018, by and among GlaxoSmithKline Intellectual Property Development Ltd., Glaxo Group Limited and Dermavant Sciences GmBH (Filed With SEC on May 14, 2021)